| Product Name | Linifanib(ABT-869; AL-39324; RG3635) |
|---|---|
| CAS | 796967-16-3 |
| Formula | C21H18FN5O |
| MW | 375.40 |
| MDL | MFCD11840918 |
| Appearance | White to gray powder |
| Size | Availability | Price(USD) | VIP Price (USD) | Quantity |
|---|---|---|---|---|
| 5 mg | 3-5days | ¥400.00 | Visible after login | |
| 10 mg | 3-5days | ¥650.00 | Visible after login | |
| 25 mg | 3-5days | ¥1160.00 | Visible after login |
| Product Name | Linifanib(ABT-869; AL-39324; RG3635) |
|---|---|
| CAS | 796967-16-3 |
| Formula | C21H18FN5O |
| MW | 375.40 |
| MDL | MFCD11840918 |
| Appearance | White to gray powder |
Linifanib (formerly RG3635, ABT869, AL39324) is an orally bioavailable and ATP-competitive inhibitor of multiple kinases (e.g. VEGFR/PDGFR) with potential antitumor activity. Its IC50 values are 4 nM, 3 nM, 3 nM/4 nM, and 66 nM for KDR, CSF-1R, Flt-1/3, and PDGFRβ, respectively. Linifanib has strong antitumor efficaciousness in vivo and outstanding anti-proliferative activity in vitro.